Interviews

Turbocharging Phenotypic Screening with AI to Target mRNA Biology

by Andrii Buvailo, PhD  (contributor )   •     

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

While the pharmaceutical world is investigating biologics or mRNA-based therapies, Yochi Slonim, Israeli technology and biotech entrepreneur and public speaker on the subject of startup building and positioning, is sticking to the classics -- small molecules -- but his strategy comes with a twist.

Yochi is not a classically trained pharmaceutical scientist. His background is in software, where he has created and sold start-ups that were acquired by large corporations like HP, UGS, and BMC. Yochi took his expertise in software/artificial intelligence (AI) and co-founded Anima Biotech in 2014 to help create a novel way to identify mRNA-targeting drugs and their mechanisms of action.

#advertisement
AI in Drug Discovery Report 2025

Continue reading

This content available exclusively for BPT Mebmers

Topics: AI & Digital   

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email